Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Venetoclax Plus BTK Inhibitor–Based Combinations Represent Promising Avenue in CLL/SLL

January 9th 2025

Supriya Gupta, MD, details pros/cons with different BTK inhibitors and promising combination therapies in CLL, as well as how liso-cel is affecting care.

Duvelisib Plus Venetoclax Is Active in Relapsed/Refractory CLL and Richter Syndrome

January 9th 2025

Duvelisib plus venetoclax was active in relapsed/refractory CLL and Richter syndrome with high-risk, TP53-aberrant disease after BTK inhibition.

Tailoring Treatment Approaches for Fit vs Unfit CLL Patients

January 8th 2025

A panel of medical experts continues their discussion surrounding an array of treatment options for CLL.

Fixed-Duration Zanubrutinib/Venetoclax Shows Efficacy in R/R Chronic Lymphocytic Leukemia

January 8th 2025

Fixed-duration zanubrutinib/venetoclax elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL

January 7th 2025

Nirav N. Shah, MD, MSHP, details how BTK degraders could fill an unmet need in pretreated CLL/SLL and highlights promising data seen with NX-5948.

Recent Guideline Updates in the Frontline Management of CLL

January 6th 2025

Dr Niemann provides an overview of the evolving treatment landscape of CLL.

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

December 19th 2024

Venetoclax-based treatment was associated with poorer outcomes in CLL previously treated with a BTK inhibitor and naive to chemotherapy.

The OncFive: Top Oncology Articles for the Week of 12/8

December 14th 2024

Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL

December 10th 2024

Pirtobrutinib improved progression-free survival in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL

December 10th 2024

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.

First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL

December 10th 2024

First-line pirtobrutinib plus venetoclax and obinutuzumab generated high uMRD6 remission rates among patients with chronic lymphocytic leukemia.

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL

December 10th 2024

Sonrotoclax plus zanubrutinib produced responses and was well tolerated in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies

December 9th 2024

Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.

Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz

December 9th 2024

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Fixed-Duration Acalabrutinib/Venetoclax Combo Improves PFS in Frontline CLL

December 8th 2024

Acalabrutinib plus venetoclax, with or without obinutuzumab, improved PFS over SOC chemoimmunotherapy in patients with treatment-naive CLL.

Epcoritamab Monotherapy Induces Complete Responses in R/R CLL

December 8th 2024

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

TRANSCEND CLL 004 Analysis Proposes Meaningful Change Thresholds for PRO Measures in R/R CLL

December 4th 2024

Meaningful thresholds for interpreting changes in 3 EORTC QLQ-CLL17 domain scores have been identified in a PRO analysis of the TRANSCEND CLL 004 trial.

OncLive’s November Roundup of Key FDA Approvals in Oncology

December 3rd 2024

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

Revisit Every OncLive On Air Episode From November 2024

December 2nd 2024

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL

November 21st 2024

NX-5948 has received PRIME designation from the EMA for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.